Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISI

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by equities research analysts at Evercore ISI from $220.00 to $260.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s price objective would suggest a potential upside of 72.44% from the stock’s previous close.

A number of other research firms have also recently weighed in on ASND. Oppenheimer decreased their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Wedbush reiterated an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 11th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $197.36.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND traded up $6.69 during trading hours on Tuesday, hitting $150.77. The company’s stock had a trading volume of 161,410 shares, compared to its average volume of 482,744. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The stock has a fifty day simple moving average of $132.65 and a 200-day simple moving average of $132.39. The company has a market capitalization of $9.15 billion, a P/E ratio of -18.59 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, equities analysts predict that Ascendis Pharma A/S will post -7.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $28,000. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter valued at $30,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. grew its holdings in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 328 shares during the period. Finally, Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.